LivaNova at Morgan Stanley conference: growth plan leans on core units

LivaNova raised full-year growth guidance to 9.5%-10.5% for cardiopulmonary, up 250bps from its initial outlook, and to 7%-8% for epilepsy from 6%-7%, supported by pricing, reimbursement, supply-chain improvements and share gains. Epilepsy reimbursement for new implants and battery replacements increased about 50%, while the CORE-VNS study reported a 77% median seizure reduction across more than 600 patients. Management is targeting 80% free-cash-flow conversion by 2028 despite elevated capex through 2025, and sees obstructive sleep apnea as a major growth platform following PolySync's 85% responder rate; commercial launch is targeted for 2027 with a meaningful ramp in 2028.

Analysis

The investable issue is whether LIVN can convert recent execution into a higher-quality earnings base before its OSA program contributes. Near-term upside is principally operating leverage: cardiopulmonary capacity utilization, improved mix and epilepsy reimbursement can lift gross margin, but elevated manufacturing, ERP and digital spending means EBITDA gains may not translate into free cash flow for the next 12-18 months. The stated 2028 cash-conversion objective should therefore not be capitalized at face value until quarterly capex and working-capital trends demonstrate a credible glide path.

OSA is strategically valuable but should be assigned a probability-weighted option value, not treated as a 2027 revenue driver. LIVN's addressable-patient expansion could pressure incumbent Inspire Medical Systems (INSP) if clinical differentiation holds in broader, more complex patients; however, clinical responder-rate comparisons across trials are not equivalent to real-world adoption, and surgeon training, reimbursement and PMA timing will determine commercial value. The more immediate competitive effect is likely on INSP's terminal multiple rather than its 2026-27 revenue, while TMO's supply relationship is too small to be a material earnings catalyst.

Consensus may be underestimating the earnings durability of the replacement and disposable revenue base, but also overestimating how quickly better clinical evidence changes referral behavior. A high reimbursement step can initially manifest as price and lower discounting rather than a sustained acceleration in implants; tougher comparisons and procedure-volume conversion are the key 1-3 month checks. The transcript contains dated launch and regulatory references, so this is not independently actionable conference news without confirming current PMA status, updated guidance and the present valuation versus INSP.

Key Decisions for Investors

• Maintain or initiate a modest long LIVN only after confirming current-year guidance and OSA regulatory status; target a 6-12 month holding period driven by core revenue conversion and margin delivery, not OSA sales. Size as a 1-2% risk position given the capex/approval uncertainty.
• Use LIVN versus INSP as a 12-18 month relative-value watchlist pair: long LIVN / short INSP only if updated OSA labeling confirms broader eligibility and LIVN trades at a material discount on forward EV/sales. The thesis is multiple convergence; avoid entry solely on cross-trial responder-rate claims.
• Set downside triggers for LIVN: reduce exposure on a cardiopulmonary growth deceleration below mid-single digits for two quarters, epilepsy implant growth failing to outpace price, or capex remaining elevated beyond management's stated normalization window.
• No trade in TMO from the supply agreement. Reassess only if LIVN discloses meaningful contracted volumes, exclusive manufacturing economics, or supply-driven share gains that can affect TMO's specialty-diagnostics or bioproduction revenue base.